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The establishment of a robust hepatitis C virus (HCV) cell culture system and subsequent detailed characterization of the HCV life cycle was a key step toward the identification of putative antiviral targets and respective antiviral drugs.
1,2
These include direct-acting antiviral agents (DAAs) such as NS3/4A protease inhibitors, NS5A inhibitors, nucleos(t)ide and non-nucleoside polymerase inhibitors, as well as hosttargeting agents (HTAs) directed against cellular factors involved in viral entry or replication. 3 Trials investigating different drug classes with and without pegylated interferon (PegIFN) and/or ribavirin have rapidly evolved, yielding highly promising sustained virologic response (SVR) rates.
4,5
In regard to the enormous public health impact of HCV infection with an estimated 184 million anti-HCV positive persons worldwide, the recent advances in HCV drug development, together with implementation of improved HCV screening programs, have the potential to substantially reduce the burden of HCV-associated advanced liver disease including hepatocellular carcinoma.
6-9
The first-in-class NS3/4A inhibitors telaprevir and boceprevir were approved in 2011. Addition of these drugs to the PegIFN/ribavirin backbone has considerably improved response rates in HCV therapy naïve and experienced patients compared with PegIFN/ribavirin alone.
10-13
The poor side-effect profile of these IFN-based therapies, however, limits the wide clinical applicability. Proof of the principle that viral clearance can be achieved with an IFN-free DAA combination has fast-tracked design and the conduct of clinical trials investigating IFN-free DAA combinations.
14 Different HCV genotypes and multiple subtypes result in a genotype and subtype-dependent efficacy of many available DAAs. 15, 16 Furthermore, viral clearance is challenged by the presence and selection of resistance-associated variants (RAVs).
17,18
Thus, essential prerequisites for DAAs in clinical development comprise a high antiviral efficacy, a broad and at best pan-genotypic activity, as well as a high barrier to resistance. In this respect, nucleos(t)ide polymerase inhibitors display very favorable characteristics. [19] [20] [21] In addition to a high antiviral efficacy, binding to the highly conserved active site of the RNA-dependent RNA-polymerase (RdRp) and incorporation as active triphosphates into the growing HCV RNA chain terminating its elongation, confers a pan-genotypic activity. Also, the low replication fitness of emergent
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Abstract
The identification of viral and host factors involved in hepatitis C virus (HCV) replication was a key prerequisite for the discovery and further exploration of antiviral drug targets. As of today, numerous direct-acting antiviral agents (DAAs), as well as host-targeting agents (HTAs), have been developed and entered clinical testing. The goal to omit pegylated interferon due to its unfavorable side-effect profile from novel HCV therapeutic approaches led to an expedited design and competitive conduct of DAA combination trials striving for easily applicable, all-oral HCV treatments. Approval of several interferon-free regimens is awaited in the near future (2014/2015). Results of different DAA combination trials (without nucleos(t)ide polymerase inhibitors) and trials involving HTAs are reviewed herein.
HCV resistant variants clinically translates into a very favorable resistance profile of these drugs. In contrast, most nonnucleoside NS5B inhibitors have a lower antiviral efficacy. 19, 22 
31-33
The combination of the ritonavir-boosted NS3/4A protease inhibitor ABT-450/r with one of two different NNIs (ABT-072 or ABT-333) was investigated in several phase 2 studies (PILOT, Co-PILOT, AVIATOR). [34] [35] [36] The PILOT-study was a single-arm trial investigating a 12-week combination therapy of ABT-450/r (150/100 mg once daily) and ABT-072 (400 mg once daily) and ribavirin in 11 therapy-naïve, non-cirrhotic HCV genotype 1 patients with the IL28B-CC genotype. 34 Of those 91% (10 of 11 patients) achieved an SVR24. One additional patient had a viral relapse 36 weeks after treatment discontinuation (SVR36 82%). The CO-PILOT study investigated two different doses of ABT450/r (250 mg/ 100 mg and 150 mg/100 mg) in combination with ABT-333 (400 mg twice daily) and ribavirin for 12 weeks in therapynaïve HCV genotype 1-infected patients without cirrhosis (groups 1 and 2, n ¼ 19 and n ¼ 14 patients, respectively).
35
Group 3 (n ¼ 17) included therapy-experienced patients (null or partial responders to prior PegIFN therapy) who were treated with ABT-450/r (150/100 mg once daily) and ABT-333 (400 mg twice daily) and ribavirin for 12 weeks. Response rates were 89%, 79%, and 47% for groups 1, 2, and 3, respectively. The AVIATOR study enrolled noncirrhotic HCV genotype 1 therapy-naïve patients and patients with prior null response to a PegIFN-based therapy.
36 In 14 different treatment arms, different doses of ABT450/r (200/100 mg, 150/100 mg, or 100/100 mg once daily) were investigated in combination with ABT-333 (400 mg twice daily) or/and the NS5A inhibitor ABT-267 (25 mg once daily), with and without ribavirin. Therapy durations ranged from 8 to 24 weeks. Of 41 treatment-naïve patients who were randomized to treatment with ABT-450/r (150/100 mg once daily), ABT-333 and ribavirin for 12 weeks, 85.4% achieved an SVR12. Other study arms (combination of ABT450/r, ABT-267 and ribavirin, or triple DAA combinations) are reviewed below. The ZENITH trial was designed to study combination therapy of the NS3/4A protease inhibitor telaprevir (1125 mg twice daily) and the non-nucleoside polymerase inhibitor lomibuvir (VX-222; 400 mg twice daily), with ribavirin in 23 HCV genotype 1a and 23 genotype 1b therapy-naïve patients without cirrhosis. 37 Patients with undetectable HCV RNA at Interferon-Free Strategies without a Nucleoside/Nucleotide Analogue Welzel, Zeuzem 49 week 4 and 8 (26% and 22% of the genotype 1a and genotype 1b patients, respectively) were eligible to discontinue treatment at week 12. Of those, 73% genotype 1a and 71% genotype 1b patients achieved an SVR12. The ribavirin free-treatment arms were discontinued due to high breakthrough rates meeting predefined stopping criteria.
The phase 2 ANNAPURNA study tested the combination of the ritonavir-boosted NS3/4A protease inhibitor danoprevir, the non-nucleoside polymerase inhibitor setrobuvir, and mericitabine, a nucleoside analog polymerase inhibitor and ribavirin for 12 to 24 weeks in noncirrhotic treatment-naïve HCV genotype-1-infected patients. 38 The combination of DNV/r (100/100 mg twice daily), setrobuvir (800 mg twice daily on day 1, followed by 400 mg twice daily thereafter), and ribavirin was investigated in genotype 1a patients for 24 weeks (Arm C), and in genotype 1b patients for 12 weeks (Arm E). Treatment Arm C met a predefined futility rule due to a high viral breakthrough rate. SVR rates for Arm E were reported with 77.7% at The American Association for the Study of Liver Diseases (AASLD) 2013.
38
Another study, combining the NS3/4A protease inhibitor simeprevir and TMC647055, a non-nucleoside polymerase inhibitor and low-dose ritonavir with and without ribavirin for 12 weeks is currently planned (►Table 2).
39
Clinical Trials Investigating the Combination of a NS3/4A Protease Inhibitor and a NS5A Inhibitor AE Ribavirin Proof of concept that eradication of HCV is possible by the combination of a NS3/4A protease inhibitor and a NS5A inhibitor was first demonstrated in a small exploratory trial.
14 In this study, 11 HCV genotype 1 null responders to prior PegIFN/ ribavirin therapy were treated with the NS3/4A protease inhibitor asunaprevir (ASV, 600 mg twice daily) and the first-in-class NS5A inhibitor daclatasvir (DCV, 60 mg once daily) for 24 weeks. Overall, 36% of the patients achieved an SVR. Virologic response rates differed by HCV subtype, as viral clearance was achieved in two of two HCV genotype 1b-infected patients, but in only two of nine (22, 2%) HCV genotype-1a-infected patients due to high viral breakthrough rates. Therapeutic efficacy of this dual DAA regimen administered for 24 weeks was further investigated in several phase 2 trials conducted in Japan and in the United States.
40-42
Two Japanese studies enrolled HCV genotype 1b patients without cirrhosis who were intolerant/ineligible and/or nullresponder patients.
40, 41 Response rates in prior null responders, as reported in one of the trials, were 100%; in the other trial, response rates of 63.6% and 90.5% were reported in PegIFN intolerant/ineligible (n ¼ 22) and null-responder (n ¼ 10) patients, respectively.
40,41
Of note, in these Japanese phase 2 trials asunaprevir dose was adjusted from 600 mg twice daily to 200 mg twice daily due to observed hepatotoxicity at higher doses. 43 The U.S.
study investigated different dosing regimens of asunaprevir (200 mg twice daily vs. 200 mg once daily) in HCV genotype1b null-responders without cirrhosis: SVR rates ranged from 65 to 78%.
43
At AASLD 2013, SVR24 results of a Japanese phase 3 trial were reported to be 87.4% in IFN-ineligible/intolerant patients (n ¼ 135) and 80.5% in prior null-responders (n ¼ 87) who received asunaprevir and daclatasvir (100 mg twice daily and 60 mg once daily) for 24 weeks. 44 Importantly, baseline factors such as compensated liver cirrhosis did not affect response rates. Another phase 3 trial ("Hallmark-Dual") currently investigates the same regimen in therapy-naïve patients, prior null-/partial-responders and patients with PegIFN ineligibility or intolerance; results were not yet presented.
45
Efficacy of daclatasvir in combination with the NS3/4A protease inhibitor simeprevir is currently studied in a pharmaceutical cross-collaboration. 46 In this open-label phase 2 study, 140 HCV genotype 1b-infected, therapy-naïve patients or patients with prior null response to PegIFN and ribavirin therapy were randomized to receive DCV (30 mg once daily) and simeprevir (150 mg once daily) either with or without ribavirin for 12 weeks. Patients with compensated cirrhosis (up to 35%) were included. Patients were re-randomized at week 12 to stop therapy or continue for another 12 weeks. A small pilot cohort of HCV genotype 1a-infected patients was included in this study, who received simeprevir and daclatasvir in combination with ribavirin for 24 weeks. Results of this trial are not yet available. The AVIATOR study, as outlined above, also investigated the efficacy of ABT-450/r, the NS5A inhibitor ABT-267, and ribavirin.
36 Seventy-nine therapy-naïve HCV genotype 1 patients and 45 prior null responders were treated with ABT-450/r (100/100 mg and 200/100 mg once daily for naïve and 200/100 mg once daily for prior null responders) and ribavirin for 12 weeks. SVR24 rates were as high as 89.9% and 88.9%, respectively. Results of the PEARL-1 study that investigated the efficacy of a ribavirin sparing combination of ABT-450/r (150/100 mg once daily) and ABT-267 (25 mg once daily) for 12 weeks were reported at AASLD 2013. 47 SVR12 rates in 42 Interferon-Free Strategies without a Nucleoside/Nucleotide Analogue Welzel, Zeuzem 51 This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. 1 and 2) or the ribavirin-free dual DAA combination of MK5172 (100 mg once daily) and MK8742 (50 mg once daily, arm 3). Patients infected with HCV genotype 1a were only allocated to ribavirin containing arms. SVR12 rates were 96%, 89%, and 100% for arms 1, 2, and 3, respectively. Importantly, response rates in arm 1 and 2 were found to be equally effective in HCV genotype 1a and genotype 1b patients. Also, addition of ribavirin did not provide an additional benefit for patients infected with HCV genotype 1b.
A double-blind, placebo-controlled phase 2 trial evaluated the safety, tolerability, and efficacy of 12 weeks of sovaprevir, another second-generation protease inhibitor, ACH-3102, an NS5A inhibitor and ribavirin in up to 50 treatment-naïve patients with HCV genotype 1 infection. Sovaprevir, however, was placed on partial clinical hold by the FDA due to liver enzyme elevations in a phase 1 drug-drug interaction study with ritonavir-boosted atazanavir. Treatment of patients in the above-mentioned study was continued, results have not yet been disclosed. 49 
Clinical Trials Investigating Triple DAA Combination Therapies
The combination of three DAAs, including an NS3/4A protease inhibitor, an NS5A inhibitor, and a non-nucleoside polymerase inhibitor, with or without ribavirin, has been investigated in several studies. Interim results of a phase 2 trial exploring whether the addition of the NS5A inhibitor PPI-668 to faldaprevir and deleobuvir may improve response rates in HCV genotype 1a patients were presented recently. 50 Twenty-four HCV genotype 1a-infected therapy naïve patients without cirrhosis were randomized to one of two 12-week treatment cohorts where they received faldaprevir (120 mg once daily), PPI-668 (200 mg once daily), and two different doses of deleobuvir (600 mg twice daily or 400 mg twice daily; cohort 1 and 2, respectively). A subset of the patients (n ¼ 13) was allocated to a 12-week, ribavirin-free triple DAA treatment arm (cohort 3). At the time of the AASLD 2013 presentation one patient harboring the NS5A variant Q30L-Y93H at baseline had experienced viral breakthrough after week 5, and 13 patients had achieved SVR4. Another phase 2, open-label study examined the ribavirinfree combination of daclatasvir (60 mg once daily), asunaprevir (200 mg twice daily) and the non-nucleoside NS5B inhibitor BMS-791325 (75 or 150 mg twice daily) for 12 or 24 weeks in 66 treatment-naïve HCV genotype-1-infected patients without cirrhosis. 51 Based on a modified intent-to-treat analysis, 92% of the patients achieved an SVR12. Results of an expansion cohort evaluating this triple DAA regimen in a larger number (n ¼ 166) of therapy-naïve patients including cirrhotic patients were presented at AASLD 2013. 52 SVR4 rates were similar in the BMS-791325, 150 mg, and 75 mg groups (91.7% and 92.3%, respectively); 86.4% (13 of 15 patients) of the cirrhotic patients achieved an SVR4. Trials assessing this combination in mainly HCV genotype-4-infected patients and in prior null responders are currently planned.
In the AVIATOR study, triple DAA therapy with ABT450/r, ABT-267, and ABT-333 in combination with ribavirin for 12 weeks yielded high SVR rates of 97.5% and 93.3% in HCV genotype 1-infected, therapy-naïve patients and null responders to prior PegIFN/ribavirin therapy, respectively.
36
Sustained virologic response rates were lower in the 8-week arm (87.5%) as well as in a ribavirin-sparing therapy arm (87.3%). Ribavirin dose reductions mainly due to hemolytic anemia did not impact SVR rates.
53
Ongoing phase 3 studies investigate virologic response rates of these triple DAA regimens in combination with ribavirin in HCV-genotype-1 infected, noncirrhotic, therapy naïve and experienced patients (SAPPHIRE-1 and SAPPHIRE-II) or in patients with cirrhosis (TURQUOISE-II) (►Table 2). [54] [55] [56] Preliminary results from the SAPPHIRE-1
and SAPPHIRE-II study were released recently. Overall SVR rates were 96% in both trials, and final results are awaited.
57
Also, treatment efficacy of ABT450/r, ABT-267, and ABT-333 is currently studied with and without ribavirin in HCV genotype-1b-infected therapy naïve and experienced patients (e.g., PEARL-II, PEARL-III) and in patients with HCV genotype 1a infection (PEARL-IV).
58-60

DAA Monotherapy
Data on prolonged monotherapy with an NS3/4A protease inhibitor are only available from a small Japanese study investigating telaprevir monotherapy for 24 weeks in patients infected with HCV genotype 1b. 61 Response rates were very unfavorable due to the rapid selection of RAVs. Until recently, the concept of NS3/4A monotherapy was not further pursued. At AASLD 2013, however, highly interesting data of the C-SPIRIT study were presented. Results of this study are certainly stimulating, as they provide first evidence that second-generation protease inhibitors with a high barrier to resistance may be successful in combination with only ribavirin in selected patients. 73 Study participants were randomized to receive five weekly doses of miravirsen (3 mg, 5 mg, or 7 mg per kilogram of body weight) or placebo subcutaneously. Administration of miravirsen resulted in a dose-dependent reduction in HCV RNA of up to 3 log 10 IU per milliliter in patients randomized to the highest dose group. Alisporivir (ALV, DEB025) is a first-in class oral HTA that inhibits cyclophilin A, a cellular enzyme with isomerase and chaperone activity. Cyclophilin A has been shown to play an important role in HCV replication and assembly through interaction with HCV NS5A and NS5B proteins. Although alisporivir is a structural analog of cyclosporine A, the alisporivir-cyclophilin complex does not inhibit calcineurin, and therefore lacks immunosuppressive activity. [74] [75] [76] Alisporivir is active against all HCV genotypes and has a high barrier to resistance. 
Host-Targeting Agents
81,82
Summary and Perspectives HCV drug development is currently on a competitive speedway toward the ultimate goal of a safe, well-tolerable, IFNfree, all-oral, pan-genotypic HCV therapy. Approval of nextgeneration protease inhibitors such as simeprevir, faldaprevir, and asunaprevir is expected in 2014. The very recent approval of sofosbuvir, a nucleotide polymerase inhibitor that, in combination with ribavirin, shows excellent efficacy in HCV genotype 2 and 3 infections, and together with PegIFN $ 90% SVR rates for patients infected with HCV genotype 1, has again changed the current HCV treatment landscape the current HCV treatment landscape. Other PegIFN-free DAA combinations that include for example, faldaprevir and deleobuvir, asunaprevir and daclatasvir, simeprevir and daclatasvir, as well as ABT-450, ABT-267, and ABT-333 will likely become available late 2014/early 2015. Without the backbone of potent nucleotide polymerase inhibitors, combinations of two or more DAAs will be required to maximize efficacy and minimize the emergence of RAVs, particularly in difficult to treat genotypes such as HCV genotype 1a. Second-generation NS3/4A protease inhibitors and potentially NS5A inhibitors may also exhibit high barriers to resistance. As to ribavirin, its relevance varies among different DAA combinations tested. Available data suggest that it particularly benefits treatment of more difficult-to-cure subtypes such as HCV genotype 1a. It should be noted, that efficacy of several DAA combinations are either not yet examined in patients with liver cirrhosis, or results of these studies are still pending. Generally, future efforts in HCV drug development should essentially focus on the safety and efficacy in patients with more advanced liver disease and other special populations such as patients with end-stage renal failure, transplanted patients, and HIV/HCV coinfected patients. The future role of HTAs still needs to be defined.
